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The success of renal transplantation may be coun-
terbalanced by serious adverse medical events. The
effect of immunosuppression on the incidence of de
novo neoplasms among kidney recipients should be
monitored continuously. Using data from the Scientific
Registry of Transplant Recipients, we studied the as-
sociation of induction therapy by immunosuppression
with antilymphocyte antibodies, with the develop-
ment of de novo neoplasms. The study population in-
cluded more than 41 000 recipients who received a ca-
daveric first kidney transplant after December 31, 1995,
and were followed through February 28, 2002.
Using Cox regression models, we estimated time to
development of two types of malignancy: de novo
solid tumors and post-transplant lymphoproliferative
disorder (PTLD). We made adjustments for several pa-
tient demographic factors and comorbidities.
Induction therapy was significantly associated with a
higher relative risk (RR) of PTLD (RR = 1.78, p < 0.001),
but not with a greater likelihood of de novo tumors
(RR = 1.07, p = 0.42). Treatment with maintenance
tacrolimus vs. cyclosporine showed a significantly dif-
ferent RR of developing de novo tumors for recipients
with induction than for those not receiving induction
(p = 0.024). These new estimates of the magnitude
of malignancy risk associated with induction therapy
may be useful for clinical practice.
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Introduction
The incidence of malignancy is significantly higher for
organ transplant recipients than for the general popu-
lation that has not undergone transplantation. For in-
stance, the incidence of post-transplant lymphoprolifera-
tive disorder (PTLD) among kidney transplant recipients
is approximately 1%, which confers a risk of lymphoma
approximately 20-fold greater than that seen in the general
population (1). Several cross-sectional studies (2–6) sug-
gest a close relationship between immunosuppression and
incidence rates of de novo solid tumors and PTLD among
recipients of kidneys and other solid organ transplants.
As a consequence of immunosuppressive therapy to pre-
vent transplant rejection, a transplant recipient’s immune
surveillance mechanism for tumor cells is likely to be
compromised. In fact, recipients of organ transplants are
slightly more vulnerable to the development of uncommon
tumors and also have a higher incidence of some more
common tumors, such as skin cancer (2%) (6,7). Skin can-
cer (basal and squamous cell types) is the most common
tumor in both the transplant and normal population, but
transplant recipients are threefold more likely to develop
it (8).
Most PTLD is thought to be caused by transformations
of lymphoid tissue frequently resulting from uncontrolled
Epstein-Barr virus (EBV) infection or reactivation of latent
EBV infection. It afflicts many recipients of solid organ
transplants (9–11). Previous studies have shown that trans-
plant recipients at increased risk for PTLD include children
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with primary EBV infection (12) and recipients who have
been heavily immunosuppressed (11,13,14). It has been
shown that kidney recipients who receive less immuno-
suppression have a lower risk of developing PTLD (15).
Such patients include recipients of a living-related donor
kidney, as well as cadaveric kidney transplant recipients
who have never had a rejection episode and thus have not
been exposed to the most intensive post-transplant im-
munosuppression therapy.
Patients with post-transplant malignancies have higher
rates of mortality. Among all US patients with functioning
kidney transplants received between 1994 and 1996, the
total death rate was approximately 25.8 per 1000 patient
years. Moreover, the death rate from malignant diseases
was 1.9 per 1000 patient years, which represents approx-
imately 7% (1.9/25.8) of the total death rate (16).
Most of the above-cited studies investigated the amount
and duration of administered immunosuppression and
rates of post-transplant malignancy. In this study we exam-
ine the incidence of de novo tumors and PTLD in kidney
recipients exposed to specific immunosuppressive agents.
We focus specifically on the use of antilymphocyte prepa-
rations as induction therapy at time of transplantation, as
the use of these agents has been associated with an in-
crease in the severity and frequency of infection compared
with noninduction immunosuppressive regimens (17,18).
Data and Methods
The database of the Scientific Registry of Transplant Recipients (SRTR) in-
cludes extensive data for all solid organ transplant recipients in the US (19).
Major components of the SRTR data are collected by the Organ Procure-
ment and Transplantation Network (OPTN); the database also includes infor-
mation from other national sources (20). Transplant centers report known
post-transplant malignancies to the OPTN at 6 months and at each anniver-
sary following transplantation.
On the OPTN data collection forms, and therefore in the SRTR database, de
novo tumors are classified by site: bladder; breast; colorectal; liver; prostate;
renal carcinoma; skin; lung; stomach; vulva, perineum or penis, and scrotum;
other cancer; and primary unknown. Post-transplant lymphoproliferative dis-
order is classified as polymorphic hyperplasia, monomorphic or polymorphic
PTLD (lymphoma), multiple myeloma, plasmacytoma, or Hodgkin’s disease.
For this study, we defined induction therapy as immunosuppression dur-
ing the initial transplant hospitalization with one of the following agents:
equine antithymocyte globulin (ATGAM®, or ATG, Pharmacia and Upjohn
Inc., Kalamazoo, MI), rabbit antithymocyte globulin (Thymoglobulin®, Sang-
Stat Medical Corp., Fremont, CA), muromonab-CD3 (Orthoclone OKT3®,
Ortho Pharmaceutical Corporation, Biotech Division, Raritan, NJ), da-
climuzab (Zenapax®, Protein Design Laboratories, Fremont, CA), basilix-
imab (Simulect®, Novartis Pharmaceuticals Corporation, East Hanover, NJ),
NRATG/NRATS (Nashville rabbit antithymocyte globulin/Nashville rabbit an-
tithymocyte serum), or T10B9 (Medimmune, Medimmune Inc., Gaithers-
burg, MD). Treatment by any other immunosuppressive agent at the time of
transplantation was not classified as induction therapy. Several patient risk
factors were also studied, including age, gender, race (White, Asian, Black,
other), ethnicity (non-Hispanic, Hispanic), body weight, Hepatitis C antibody
screen (positive, negative, unknown), Hepatitis B core antibody (positive,
negative, unknown), time since first dialysis, presence of diabetes, and year
of transplantation. Information on EBV infection, a risk factor for developing
PTLD, is not complete in the SRTR database, and thus this factor was not
examined in the analyses.
The study population includes all cadaveric first kidney transplant recipients
who received a transplant between January 1, 1996, and February 28, 2002.
These patients were followed through February 2002. For both de novo
tumor and PTLD analyses, recipients with pre-existing malignancies were
excluded. For de novo tumor analyses, we also excluded recipients who
had less than 6 months of follow up after transplantation and recipients
with a first tumor diagnosis in the first 6 months following transplantation
(total of 8%), as such tumors were likely unrelated to induction therapy.
These two exclusions resulted in a study group of 38 191 recipients for de
novo tumor analyses. We did not make these last two exclusions for the
PTLD analyses, as PTLD can develop early after transplantation. The early
development of PTLD following renal transplantation has been reported in a
number of studies (11,21). The study group for the PTLD analyses included
41 686 recipients.
A logistic regression model, including all the above-listed patient factors,
was used to identify groups of patients with higher likelihood of receiving
induction therapy. Multivariate Cox proportional hazards regression models,
also adjusted for all the above-listed patient factors, were used to analyze
rates of de novo tumors and PTLD. The two Cox models are based on time
from transplant to the first reported de novo tumor or PTLD, censored at
death or the end of the study (February 2002). All models were fitted using
SAS 8.2 (SAS Institute, Inc., Cary, NC).
Additional analyses were performed including separate categories for
equine antithymocyte globulin (ATG), rabbit antithymocyte globulin,
muromonab-CD3, daclimuzab, and basiliximab in the model. The remain-
ing medications for induction therapy, T10B9 (Medimmune) (<0.1%) and
NRATG/NRATS (0.6%), were grouped together in a separate category.
Further analyses were also performed to investigate the effect of different
maintenance therapies on the risk of de novo tumors and PTLD, for pa-
tients with and without induction therapy. Two calcineurin inhibitors were
chosen for comparison: tacrolimus and cyclosporine. Other comparisons
were also made between two antimetabolites: azathioprine and mycophe-
nolate mofetil (MMF). Both comparisons were adjusted for all the patient
factors included in the main model as well as for the effects of both an-
timetabolites and calcineurine inhibitors.
Results
Our data showed that 45% of patients received induction
therapy at the time of transplantation. Results from a logis-
tic model for identifying groups of patients more likely to re-
ceive induction therapy showed that pediatric (<18 years of
age) recipients were more likely to receive induction ther-
apy than recipients older than 50 years of age (odds ratio =
1.42, p < 0.001); all other age groups had a likelihood sim-
ilar to that of patients older than 50 years. Increased odds
of receiving induction therapy were also observed for fe-
males compared with males and for a more recent year of
transplantation, while decreased odds were observed for
Whites and Asians compared with Blacks, and for recipi-
ents with positive Hepatitis B core antibody.
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Table 1: Counts of first cadaveric kidney transplant recipients and percentages with de novo solid tumors and post-transplant lympho-
proliferative disorder, by year of transplantation
De novo solid tumors Post-transplant lymphoproliferative disorder
Transplantation (year) Transplants (n) With tumor (%) Transplantation (year) Transplants (n) With tumor (%)
1996 6585 2.34 1996 6587 0.62
1997 6607 2.15 1997 6608 0.61
1998 6829 2.23 1998 6836 0.51
1999 6835 1.40 1999 6841 0.41
2000 6766 0.80 2000 6772 0.25
20011 4569 0.39 2001 6912 0.29
20022 1130 0.00
All 38 191 1.61 All 41 686 0.49
1Includes January through August 2001 only.
2Includes January through February 2002 only.
Table 2: Average length of follow up (in years) in cross-tabulation of induction therapy, by de novo solid tumors and post-transplant
lymphoproliferative disorder
De novo solid tumors Post-transplant lymphoproliferative disorder
Yes No Yes No
With induction therapy 2.83 3.42 1.77 3.12
Without induction therapy 3.25 4.05 2.18 3.86
Table 3: Baseline factors and relative risk (Cox) of developing a de novo solid tumor (n = 38 191, de novo solid tumors = 616)
Factor Mean or % RR 95% CI p-value
Induction therapy (yes vs. no) 44.6% 1.07 (0.91, 1.26) 0.42
Age (per 10 years older) 47.52 1.80 (1.68, 1.93) < 0.0001
Gender (male vs. female) 60.3% 1.33 (1.12, 1.59) 0.002
Race (white vs. Black) 64.1% 1.98 (1.58, 2.50) < 0.0001
Race (Asian vs. Black) 4.3% 0.90 (0.51, 1.60) 0.72
Race (other vs. Black) 2.5% 0.36 (0.11, 1.15) 0.085
Ethnicity (non-Hispanic vs. Hispanic) 85.4% 3.33 (2.18, 5.07) < 0.0001
Weight (per 10 kg heavier) 76.49 1.03 (0.97, 1.09) 0.34
Hepatitis C antibody screen (positive vs. negative) 5.4% 0.66 (0.40, 1.10) 0.11
Hepatitis C antibody screen (unknown vs. negative) 10.9% 1.07 (0.81, 1.41) 0.62
Hepatitis B core antibody (positive vs. negative) 7.0% 1.12 (0.80, 1.57) 0.50
Hepatitis B core antibody (unknown vs. negative) 28.0% 0.93 (0.76, 1.13) 0.46
Time since first dialysis (per additional year) 3.04 1.01 (0.98, 1.04) 0.43
Year of transplantation (per additional year after 1996) 1998 1.31 (1.22, 1.41) < 0.0001
Diabetes (absent vs. present) 67.0% 1.59 (1.30, 1.95) < 0.0001
Results for missing categories are not shown. The following variables had missing values in the database (percentage missing shown
in parentheses): weight (25%), Hepatitis C antibody screen (1%), Hepatitis B core antibody (1%), time since first dialysis (12.7%), and
diabetes (7.3%).
Of the 38 191 cadaveric first kidney transplant recip-
ients who had at least 6 months of follow up after
transplantation, 616 (1.61%) developed de novo tumors.
Of the 41 686 recipients without the above follow-up time
restriction, 181 (0.43%) developed PTLD.
Table 1 summarizes descriptive statistics including counts
of patients and percentages with de novo tumors and
PTLD by year of transplantation. Table 2 shows the av-
erage length of follow up (in years) in a cross-tabulation of
induction therapy by de novo tumors and PTLD. Although
the follow-up period for patients with de novo tumors was
6 months longer in our analysis, the markedly shorter aver-
age length of follow up for patients with PTLD compared
with that for patients with de novo tumors, as seen in
Table 2, indicates earlier incidence of PTLD. Mean or per-
cent values of the factors examined in the analyses are
shown in the second column of Tables 3 and 4.
Figures 1 and 2 show the estimated percentages, obtained
from the unadjusted Kaplan-Meier survival curves, of pa-
tients with de novo tumors and PTLD, respectively, strati-
fied by whether or not the patient received induction ther-
apy. The curves for de novo tumors (Figure 1) show similar
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Table 4: Baseline factors and relative risk (Cox) of developing post-transplant lymphoproliferative disorder (n = 41 686, PTLD = 181)
Factor Mean or % RR 95% CI p-value
Induction therapy (yes vs. no) 45.8% 1.78 (1.31, 2.40) 0.0002
Age (per 10 years older) 47.67 0.86 (0.77, 0.95) 0.003
Gender (male vs. female) 60.2% 1.43 (1.04, 1.96) 0.028
Race (White vs. Black) 64.0% 1.45 (1.00, 2.12) 0.052
Race (Asian vs. Black) 4.3% 1.90 (0.98, 3.69) 0.057
Race (other vs. Black) 2.5% 0.88 (0.27, 2.86) 0.83
Ethnicity (non-Hispanic vs. Hispanic) 85.4% 1.79 (1.04, 3.07) 0.037
Weight (per 10 kg heavier) 76.63 0.89 (0.82, 0.97) 0.012
Hepatitis C antibody screen (positive vs. negative) 5.3% 0.70 (0.30, 1.61) 0.40
Hepatitis C antibody screen (unknown vs. negative) 10.7% 0.52 (0.28, 0.98) 0.042
Hepatitis B core antibody (positive vs. negative) 7.0% 1.15 (0.64, 2.07) 0.65
Hepatitis B core antibody (unknown vs. negative) 27.4% 1.22 (0.86, 1.73) 0.26
Time since first dialysis (per additional year) 3.07 0.97 (0.89, 1.04) 0.36
Year of transplantation (per additional year after 1996) 1999 1.10 (0.99, 1.23) 0.087
Diabetes (absent vs. present) 67.3% 1.35 (0.90, 2.02) 0.15
Results for missing categories are not shown. The following variables had missing values in the database (percentage missing shown

































Figure 1: Rates of developing de novo solid tumors, with and
without induction therapy.
percentages of patients developing tumors with and with-
out induction therapy. These percentages were compared
using a log-rank test that resulted in a p-value of 0.31. In
contrast, the percentage of patients with PTLD (Figure 2)
was significantly higher for those with induction therapy
(p = 0.005). During the first 6 months following transplant,
the difference between the two groups’ rates was small.
The apparent increase suggested by the undulating pat-
terns in Figures 1 and 2 at each anniversary is likely a reflec-
tion of imprecise reporting of the date of first malignancy
diagnosis during each annual follow-up visit.
The results of fitting the two multivariate Cox models to
the data are shown in Tables 3 and 4. Table 3 provides re-
sults of a model for time to the development of de novo


















p = 0.005 
Figure 2: Rates of developing post-transplant lymphoprolif-
erative disorder, with and without induction therapy.
provides analogous model results for PTLD (starting at time
of transplantation). The tables show the relative risk (RR) of
malignancy according to induction therapy and several pa-
tient factors, together with 95% confidence intervals and
p-values for testing the hypothesis that the corresponding
model parameter = 0.
Induction therapy was significantly associated with higher
risk (RR = 1.78, p < 0.001) of developing PTLD (Table 4),
but not of developing de novo tumors (RR = 1.07, p =
0.42) (Table 3). The RR of PTLD indicates that the risk of
developing PTLD is approximately 1.8-fold higher among
recipients of induction therapy. Greater risk of PTLD was
also significantly associated with younger recipient age
(RR = 0.86 per 10 years older), males compared with
females (RR = 1.43), non-Hispanic ethnicity compared
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Table 5: Relative risk of developing de novo solid tumors, by specific medications for induction therapy (n = 38 191, de novo solid
tumors = 616)
Factor1 % RR 95% CI p-value
Induction: ATG 9.6 1.24 (0.97, 1.58) 0.084
Induction: rabbit antithymocyte globulin 4.6 1.53 (0.92, 2.56) 0.10
Induction: muromonab-CD3 10.9 0.85 (0.65, 1.11) 0.22
Induction: daclimuzab 7.6 1.06 (0.73, 1.54) 0.77
Induction: basiliximab 11.2 1.12 (0.79, 1.59) 0.54
Induction: No 55.4 1.00 Ref
1Model adjusted for age, gender, race, ethnicity, weight, Hepatitis C antibody screen, Hepatitis B core antibody, time since first dialysis,
year of transplantation, and diabetes.
Induction with T10B9 (Medimmune) (<0.1%) and NRATG/NRATS (0.6%) are not shown in the table.
P-value for testing differences between the specific medications for induction therapy in the model: 0.18.
with Hispanic (RR = 1.79), and recipients with lower body
weight (RR = 0.89 per 10 kg heavier). Greater risk of de
novo tumors was significantly associated with older recip-
ient age (RR = 1.80 per 10 years older), males compared
with females (RR = 1.33), White race compared with Black
(RR = 1.98), non-Hispanic ethnicity compared with His-
panic (RR = 3.33), absence of diabetes (RR = 1.59), and
a more recent year of transplantation (RR = 1.31). Table 1
shows that the percentage of patients with de novo tumors
or PTLD decreased for a more recent year of transplanta-
tion. This decrease is likely the result of the relatively short
length of follow up for more recently transplanted patients.
The effect of including indicators for the specific medica-
tions for induction therapy in the model for de novo tumors
was not significant (p = 0.19). However, Table 5 shows a
trend (RR = 1.24) of borderline significance (p = 0.08) to-
wards a higher risk of de novo tumors for recipients receiv-
ing induction therapy with ATG compared with those who
received no antilymphocyte induction. No significant differ-
ences were found among the specific medications for in-
duction therapy in the model for de novo tumors (p = 0.18).
The effect of including indicators for the specific medica-
tions for induction therapy in the model for PTLD was highly
significant (p = 0.010). Table 6 shows that, except for ATG
(RR = 1.50, p = 0.10), the risk of developing PTLD was sig-
nificantly higher for recipients that received any of the anti-
Table 6: Relative risk of developing post-transplant lymphoproliferative disorder, by specific medications for induction therapy (n = 41 686,
post-transplant lymphoproliferative disorder = 181)
Factor1 % RR 95% CI p-value
Induction: ATG 9.0 1.50 (0.93, 2.43) 0.10
Induction: rabbit antithymocyte globulin 5.7 3.00 (1.53, 5.89) 0.001
Induction: muromonab-CD3 10.1 1.71 (1.12, 2.63) 0.014
Induction: daclimuzab 8.1 1.92 (1.08, 3.41) 0.027
Induction: basiliximab 12.4 1.83 (1.05, 3.18) 0.032
Induction: no. 54.2 1.00 Ref
1Model adjusted for age, gender, race, ethnicity, weight, Hepatitis C antibody screen, Hepatitis B core antibody, time since first dialysis,
year of transplantation, and diabetes.
Induction with T10B9 (Medimmune) (<0.1%) and NRATG/NRATS (0.6%) are not shown in the table.
P-value for testing differences between the specific medications for induction therapy in the model: 0.34.
lymphocyte induction regimens compared with those who
received no antilymphocyte induction. As for the model
for de novo tumors, no significant differences were found
among the specific medications for induction therapy in the
model for developing PTLD (p = 0.34).
The effect of receiving maintenance with tacrolimus com-
pared with that of maintenance with cyclosporine on the
risk of de novo tumors and PTLD was analyzed, and com-
parisons between these effects were made for recipients
with and without induction therapy. Of all kidney recipi-
ents who received induction therapy (45%), 55.7% were
reported to have received maintenance with cyclosporine,
34.3% received maintenance with tacrolimus, and 6.6%
received maintenance with neither drug. Of all kidney re-
cipients not receiving induction therapy (55%), 55.7% re-
ceived maintenance with cyclosporine, 27.2% received
maintenance with tacrolimus, and 11.0% received main-
tenance with neither drug. For the purpose of making re-
liable comparisons, the remaining 3.4% of patients with
induction and 6.1% of patients without induction who
were reported to have received maintenance with both
cyclosporine and tacrolimus during the same observation
period were not included in these additional analyses.
The results for these analyses by maintenance ther-
apy showed that among kidney recipients who received
induction therapy, the risk of developing de novo tumors
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was nonsignificantly higher for those who received main-
tenance tacrolimus vs. cyclosporine (RR = 1.16, p = 0.38).
However, among recipients not receiving induction, the
risk of developing de novo tumors was significantly lower
(RR = 0.70, p = 0.020) for those who received maintenance
tacrolimus compared with those receiving maintenance cy-
closporine. This observation for maintenance tacrolimus
vs. cyclosporine was significantly different for those re-
ceiving induction than for those not receiving induction
(p = 0.024).
Similar comparisons showed that among recipients who
received induction therapy, the risk of developing PTLD
was nonsignificantly higher (RR = 1.12, p = 0.64) for those
who received maintenance tacrolimus vs. cyclosporine.
Among recipients not receiving induction, the risk of devel-
oping PTLD was significantly higher for those who received
maintenance tacrolimus vs. cyclosporine (RR = 2.03, p =
0.008). This difference in PTLD risk for recipients with and
without induction was of borderline significance only (p =
0.091).
Comparisons were also made between the effects of re-
ceiving maintenance with azathioprine and maintenance
with MMF on the risk of developing de novo tumors and
PTLD. Of all kidney recipients who received induction ther-
apy, 71.8% received maintenance with MMF, 13.2% re-
ceived maintenance with azathioprine, and 10.3% received
maintenance with neither drug. Of all kidney recipients not
receiving induction therapy, 60.6% received maintenance
with MMF, 12.0% received maintenance with azathioprine,
and 23.1% received maintenance with neither drug. The
remaining 4.7% of patients with induction and 4.3% of
patients without induction that were reported to have re-
ceived maintenance with both azathioprine and MMF dur-
ing the same observation period were excluded from these
analyses.
The risk of developing de novo tumors and that for PTLD
were not significantly modified by maintenance azathio-
prine vs. MMF whether or not the patient received induc-
tion therapy.
Discussion
Post-transplant malignancies are receiving increased atten-
tion as important complications following transplantation.
By studying a large cohort of cadaveric first kidney trans-
plant recipients, we found that induction therapy was as-
sociated with an increased risk of PTLD but not of de novo
tumors. The negative finding for de novo tumors may be
the result of the relatively short length of follow up for more
recently transplanted patients, as antilymphocyte antibody
induction therapy has been found to be associated with
higher risk for late malignancy-related death (18).
In seeking to study the effects of specific immunosuppres-
sants on the incidence of de novo tumors and PTLD, the
use of the SRTR database offered a number of advantages.
The database is large, comprehensive, and includes na-
tional data. In addition, patients were followed for an av-
erage time of approximately 4 years after transplantation,
allowing a sufficient amount of time to detect malignancy
cases. It should be emphasized, however, that there might
be underreporting of malignancy cases in these data. Thus,
ascertainment of malignancy might not be complete during
follow up. The SRTR is in the process of conducting link-
age studies using several sources of information in order
to validate the data captured in the SRTR database (20).
Preliminary data suggest underreporting of malignancies;
the results of the present study assume that such under-
reporting does not bias our findings. More recent years in
the present study appear to show an improved ascertain-
ment, as suggested by the increased relative risk by year
of transplantation (Tables 3 and 4). With more complete
ascertainment, additional factors may be identified as sig-
nificantly associated with PTLD or de novo solid tumors.
Several prior studies have focused on the relationship be-
tween post-transplant malignancy and the administered
dose or duration of immunosuppressive therapy, factors
that may contribute to the risk of post-transplant malig-
nancy (6,7,22). Information on dose and duration of ther-
apy is not complete in the SRTR database. Instead, we
investigated the relationship between post-transplant ma-
lignancy and a list of selected immunosuppressive agents
used for induction therapy, comparing malignancy rates to
those observed in the absence of antilymphocyte induc-
tion treatment. Our analyses showed statistical evidence
that the risk of developing PTLD (RR = 1.78) among ca-
daveric first kidney transplant recipients is significantly as-
sociated with induction therapy (p < 0.001). There was
also a nonsignificant trend (p = 0.42) toward a greater risk
of developing de novo tumors (RR = 1.07) among recipi-
ents who were treated with induction agents. Our analyses
also showed that in the presence of induction therapy, the
choice of maintenance tacrolimus vs. cyclosporine does
not significantly modify the risk of either de novo tumors
or PTLD. However, in the absence of induction therapy, the
choice of tacrolimus vs. cyclosporine appeared to modify
the risk of de novo tumors and PTLD. The nonsignificant
difference in post-transplant malignancy risk by tacrolimus
vs. cyclosporine for patients receiving induction therapy
may suggest that the strong immunosuppressive effect of
induction may override differences by maintenance drugs
that are observed without induction therapy. Although cer-
tain groups of patients (e.g. pediatric age group) had higher
likelihood of receiving induction therapy, our analyses are
not influenced by these differences, as the multivariate
Cox models use adjusted comparisons for patients with
the same characteristics.
In good agreement with previous studies (22–24), we
detected significant associations of increased recipient
age with an elevated risk of post-transplant de novo tu-
mors, and younger recipient age with higher risk of PTLD.
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Moreover, our study showed that other demographic fac-
tors, such as male gender, White race, and non-Hispanic
ethnicity, were also associated with post-transplant malig-
nancies. The presence of diabetes appeared to reduce the
tendency to develop de novo tumors. The reason for this
finding is unknown.
Future SRTR studies will assess the risk of specific malig-
nancy sites and associations with other immunosuppres-
sive agents. Other informative studies will investigate the
risk of post-transplant malignancies among transplant re-
cipients of other organs. For instance, we plan to use the
SRTR database to investigate the association between the
above-mentioned immunosuppressive therapies and post-
transplant malignancies among liver transplant recipients.
Previous studies have suggested that recipients of an or-
gan containing a large number of lymphocytic lineage cells
that may be infected with EBV may be at greatest risk
for developing PTLD (12,25). The SRTR database provides
an excellent source to reinvestigate these issues to bet-
ter estimate risks and modifiable factors with the goal of
decreasing the number of malignancies among solid organ
transplant recipients.
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